Eyenovia has acquired the exclusive U.S. rights to distribute and sell APP13007, a potential treatment for inflammation and pain after ocular surgery, under an agreement with Formosa Pharmaceuticals, according to a press release.
Eyenovia will make single-digit million-dollar payments to Formosa in cash and shares of Eyenovia common stock upon the signing of the agreement, upon FDA approval of APP13007 (clobetasol propionate ophthalmic nanosuspension 0.05%) and transfer of the new drug application to Eyenovia, and after the first commercial sale of APP13007, the release said. Formosa will also